Efficacy and Safety of α-Lipoic Acid Supplementation in the Treatment of Symptomatic Diabetic Neuropathy

Vinik AI , Park TS , Stansberry KB , et al. Diabetic neuropathies. Diabetologia. 2000;43: 957-973.

Vinik AI , Holland MT , Le Beau JM , et al. Diabetic neuropathies. Diabetes Care. 1992;15: 1926-1975.

Young MJ , Boulton AJM , Macleod AF , et al. A multicentre study of the prevalence of diabetic neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993;36: 150-154.

Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329: 977-986.

Sommer C. Painful neuropathies. Curr Opin Neurol. 2003;16: 623-628.

Corbett CF. Practical management of patients with painful diabetic neuropathy. Diabetes Educ. 2005;31: 523-537.

Otto M , Bak S , Bach FW , et al. Pain phenomena and possible mechanisms in patients with painful polyneuropathy. Pain. 2003;101: 187-192.

Duby JJ , Campbell KR , Setter SM , White JR , Rasmussen KA. Diabetic neuropathy: an intensive review. Am J Health Syst Pharm. 2004;61: 160-173, 175-176.

UK Prospective Diabetes Study Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352: 837-853.

Shaw JE , Zimmet PZ. The epidemiology of diabetic neuropathy. Diabetes Rev. 1999;7: 245-252.

Adler AI , Boyko EJ , Ahroni JH , et al. Risk factors for diabetic peripheral sensory neuropathy. Diabetes Care. 1997;20: 1162-1167.

Perkins BA , Greene DA , Bril VB. Glycemic control is related to the morphological severity of diabetic sensorimotor polyneuropathy. Diabetes Care. 2001;24: 748-752.

McQuay HJ , Tramer M , Nye BA , et al. A systematic review of antidepressants in neuropathic pain. Pain. 1996;68: 217-227.

Collins SL , Moore RA , McQuay HJ , Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage. 2000;20: 449-458.

Max MB , Lynch SA , Muir J , Shoaf SE , Smoller B , Dubner R. Effects of desipramin, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326: 1250-1256.

Sinrup SH , Gram LF , Brosen K , Mogensen EF. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain. 1990;42: 135-144.

Backonja M, Beydoun , Edwaards KR , et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280: 1831-1836.

Harati Y , Gooch C , Swenson M , et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998;50: 1842-1846.

Sindrup SH , Andersen G Madsen C , Smith T , Brosen K , Jensen TS. Tramodol relieves painand allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain. 1999;83: 85-90.

Ertas M , Sagduyu A , Arac N , et al. Use of levodopa to relieve pain from painful symmetrical diabetic polyneuropathy. Pain. 1998;75: 257-259.

Wright JM , Oki JC , Graves L. Mexiletine in the symptomatic treatment of diabetic peripheral neuropathy. Ann Pharmacother. 1997;31: 29-34.

Oskarsson P , Ljunggren JG , Lins PE , and the Mexiletine Study Group . Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. Diabetes Care. 1997;20: 1594-1597.

Stracke H , Meyer UE , Schumacher HE , Federlin K. Mexiletine in the treatment of diabetic neuropathy. Diabetes Care. 1992;15: 1550-1555.

Halat KM , Dennehy CE. Botanicals and dietary supplements in diabetic peripheral neuropathy. J Am Board Fam Pract. 2003;16: 47-57.

Busby RW , Schelvis JPM , Yu DS , Babcock GT , Marletta MA. Lipoic acid biosynthesis: LipA is an iron-sulphur protein. J Am Chem Soc. 1999;121: 4706-4707.

Schmidt AM , Hori O , Brett J. Cellular receptor for advanced glycation end products: implications for induction of oxidative stress and cellular dysfunction in the pathogenesis of vascular lesions. Atheroscler Thromb. 1999;14: 1521-1528.

Packer L , Witt EH , Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Rad Biol Med. 1995;19: 227-250.

Biwenga GP , Haenen GRMM , Bast A. The pharmacology of the antioxidant lipoic acid. Gen Pharmacol. 1997;29: 315-331.

Low PA , Nickander KK , Tritschler HJ. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes. 1997;46(suppl 2): S38-S42.

Bock E , Schneeweiss J. Ein Beitrag zur Therapie der Neuropathia diabetica. Müncher Med Wochenschrift. 1959;43: 1911-1912.

Ziegler D , Hanefeld M , Ruhnau, KJ , et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). Diabetes Care. 1999;22: 1296-1301.

Reljanovic M , Reichel G , Rett K , et al. Treatment of diabetic polyneuropathy with antioxidant thioctic acid (α-lipoic acid): a two-year multi-center randomized double-blind placebo-controlled trial (ALADIN II). Free Radic Res. 1999;31: 171-179.

Ziegler D , Hanefeld M , Ruhnau KJ , et al. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant α-lipoic acid: a three-week multicentre randomized controlled trial (ALADIN study). Diabetologia. 1995;38: 1425-1433.

Young MJ , Boulton AJ , MacLead AF , Williams DR , Sonksen PH. A multicenter study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993;36: 150-154.

Ruhnau KJ , Meissner HP , Finn JR , et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med. 1999;16: 1040-1043.

Ametov A , Barinov A , O’Brien P , et al. , the SYDNEY Trial Study Group . The sensory symptoms of diabetic polyneuropathy are improved with α-lipoic acid: the SYDNEY Trial. Diabetes Care. 2003;26: 770-776.

Ziegler D , Reljanovic M , Mehnert H , Gries FA. Alpha-lipoic in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes. 1999;107: 421-430.

Ziegler D. Thioctic acid for patients with sympotomatic diabetic polyneuropathy: a critical review. Treat Endocrinol. 2004;3: 173-189.

Ziegler D , Nowak H , Kempler P , Vargha P , Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid: a meta-analysis. Diabet Med. 2004;21: 114-121.